Brean Capital analyst Difei Yang sees great promise for the future of Relypsa Inc (NASDAQ:RLYP), as the pharmaceutical giant just delivered June results …
Morgan Stanley analysts gave their opinions on the outlook of healthcare companies Relypsa Inc (NASDAQ:RLYP) and Horizon Pharma PLC (NASDAQ:HZNP). Below, one analyst discuss …
Relypsa Inc (NASDAQ:RLYP) is up 6% after the company announced positive results from a pre-specified exploratory analysis of a Phase 3 trial of …
Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that results of a pre-specified exploratory analysis of the Phase 3 OPAL-HK trial of Veltassa® …
Both Relypsa Inc (NASDAQ:RLYP) and EXACT Sciences Corporation (NASDAQ:EXAS) received good news about their flagship products this week. Relypsa announced May prescription data …
Relypsa Inc Wedbush analyst Liana Moussatos reiterated an Outperform rating on shares of Relypsa Inc (NASDAQ:RLYP), with a $51 price target, after hosting an expert …
Relypsa Inc (NASDAQ:RLYP), a biopharmaceutical company, announced that on June 1, 2016, the compensation committee of the company’s board of directors granted 2 …
Many biotech analysts have turned against drug makers Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Relypsa Inc (NASDAQ:RLYP) as the former faces several fraud allegations and …
In biotech, knowing the competition is integral to understanding how drugs will succeed once they are on the market. Below, analysts weigh in …
Both Relypsa Inc (NASDAQ:RLYP) and Intercept Pharmaceuticals Inc (NASDAQ:ICPT) received welcome news recently as a competing drug to Relypsa’s Veltassa encounters some difficulties …